Manish R Sharma

Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study.

R. Schilsky, F. Meric-Bernstam, M. von Mehren, 2023, JCO precision oncology.

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

N. Segal, J. Neely, S. Suryawanshi, 2024, Journal for ImmunoTherapy of Cancer.